HTA Quarterly Fall 2025 Summary

In this edition, we continue our three-part series on France’s Early Access Program, exploring evolving evidence requirements and their implications for managing clinical and financial uncertainties. We also turn our attention to North America, examining the recent establishment of state-level Prescription Drug Affordability Boards to address high prescription drug prices in the U.S., and how the Canadian Drug Agency incorporates patient perspectives into health technology appraisals, shaping the data used for evaluations.